FDA warns Wisconsin Pharmacal over OTC drug manufacturing violations, including released rejected product and S. aureus contamination.
What happened
FDA inspected Wisconsin Pharmacal’s drug manufacturing facility in Jackson, WI, from March 3 to 7, 2025. The agency found that the quality unit allowed distribution of rejected OTC drug units, that S. aureus contamination in batches was not thoroughly investigated before release based on retests, and that laboratory computer systems lacked controls and audit trail review.
What FDA found
The quality unit lacked adequate oversight and allowed distribution of rejected OTC drug units, including about half of a rejected batch.
21 CFR 211.22The firm failed to thoroughly investigate S. aureus contamination and released batches based on passing retests without determining the root cause.
21 CFR 211.192The firm lacked controls over laboratory computer systems, including administrative privileges and audit trail review.
21 CFR 211.68(b)
What FDA wants
FDA tells the company to respond in writing within 15 working days with corrective actions and comprehensive assessments and remediation plans for its quality unit, investigations and microbial contamination, and computer system controls, or state why it cannot complete the actions and give a schedule.
Who should pay attention
- companies that buy OTC drug products from this manufacturer
- contract manufacturers with similar quality-unit oversight
- quality and lab managers responsible for microbial testing and data integrity
This is a summary. Read the original letter on fda.gov.